Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.
- Jon Zugazagoitia,
- Asunción Díaz,
- Elisabeth Jimenez,
- Juan Antonio Nuñez,
- Lara Iglesias,
- Santiago Ponce-Aix,
- Luis Paz-Ares
Front Med (Lausanne) 2017 5;4:36. Epub 2017 Apr 5.
Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain.
Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor (TKI). It showed potent EGFR signaling inhibition in experimental models, including first-generation TKI-resistant non-small cell lung cancer (NSCLC) cell lines. This preclinical efficacy did not translate into clinically meaningful treatment benefits for advanced, pretreated, molecularly unselected NSCLC patients enrolled in two parallel phase III trials. Read More